Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04314674
Other study ID # Neuroanesthesia Cerrahpasa
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date April 2020
Est. completion date December 2022

Study information

Verified date March 2020
Source Istanbul University
Contact Eren F Akcil
Phone 00905327992399
Email erenfat@yahoo.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hyperosmotic agents are used to decrease intracranial pressure. The aim of the study is to compare the effects of continuous 3% hypertonic saline (HS), bolus HS and 20% mannitol on intraoperative brain relaxation in patients with raised intracranial pressure during surgery for supratentorial tumors.


Description:

After obtaining approval from the ethics committee and informed consent, a total of 90 patients aged 18-70 years, conscious (GCS>13) and American Society of Anesthesiologists (ASA) class I-III, who had intracranial shift >0.5 cm or glioblastoma multiforme or metastatic tumor and who were scheduled for supratentorial mass resection under elective conditions, will be included in the present prospective, randomized, double-blind and placebo-controlled study. Patients with heart failure, kidney insufficiency, diabetes insipidus, electrolyte imbalance and who are unconscious will be excluded from the study.

The patients will randomized into 3 groups:

Group 1: %3 HS bolus 3 mL.kg-1 Group 2: %3 HS infusion 20 ml/h Group 3: %20 mannitol 0,6 gr.kg-1 After head fixation, all patients will be administered with HS or mannitol (over 20 minutes). Arterial blood gas (ABG) analysis (Cobas b 221 blood gas analyzer, RocheĀ®, Basel, Switzerland) will be made at 30 minute,2,4,6,8. hours. Blood sodium, potassium, chlorine, base excess, lactate levels and blood osmolarity will be recorded in each time intervals. The brain relaxation scale will be recorded at the time of dura opening.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 90
Est. completion date December 2022
Est. primary completion date April 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Elective supratentorial tumor resection

- Glioblastoma multiforme

- Metastatic tumor

- Intracranial shift >0.5 cm

- GCS>13

Exclusion Criteria:

- Renal failure

- Heart failure

- Electrolyte imbalance

Study Design


Intervention

Drug:
%3 HS bolus
After head fixation %3 HS bolus 3 ml/kg will be administered
%3 HS infusion 20 ml/h
After head fixation %3 HS 20 ml/h infusion will be administered
20% mannitol
After head fixation %20 mannitol 0.6 ml/kg will be administered

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Istanbul University

References & Publications (3)

Dostal P, Dostalova V, Schreiberova J, Tyll T, Habalova J, Cerny V, Rehak S, Cesak T. A comparison of equivolume, equiosmolar solutions of hypertonic saline and mannitol for brain relaxation in patients undergoing elective intracranial tumor surgery: a randomized clinical trial. J Neurosurg Anesthesiol. 2015 Jan;27(1):51-6. doi: 10.1097/ANA.0000000000000091. — View Citation

Hernández-Palazón J, Fuentes-García D, Doménech-Asensi P, Piqueras-Pérez C, Falcón-Araña L, Burguillos-López S. A comparison of equivolume, equiosmolar solutions of hypertonic saline and mannitol for brain relaxation during elective supratentorial craniotomy. Br J Neurosurg. 2016;30(1):70-5. doi: 10.3109/02688697.2015.1109061. Epub 2015 Nov 16. — View Citation

Quentin C, Charbonneau S, Moumdjian R, Lallo A, Bouthilier A, Fournier-Gosselin MP, Bojanowski M, Ruel M, Sylvestre MP, Girard F. A comparison of two doses of mannitol on brain relaxation during supratentorial brain tumor craniotomy: a randomized trial. Anesth Analg. 2013 Apr;116(4):862-8. doi: 10.1213/ANE.0b013e318282dc70. Epub 2013 Jan 25. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Brain relaxation score Brain relaxation score 1: Brain is under the dura, 2: Brain is in the dura level, 3:Brain is above the dura, 4: There is no pulsation in the brain 1. min before dura closure
Secondary Sodium level Blood sodium levels obtained from arterial blood gases analysis Baseline and after the drug administration 30. min, 2,4,6,8. hours
Secondary Potassium level Blood potassium levels obtained from arterial blood gases analysis Baseline and after the drug administration 30. min, 2,4,6,8. hours
See also
  Status Clinical Trial Phase
Recruiting NCT04427384 - Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
Recruiting NCT04222062 - A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease Phase 2
Completed NCT02599142 - Comparing Immobilisation Shells in Cranial Radiotherapy N/A
Completed NCT02260531 - Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases Phase 2
Not yet recruiting NCT06106997 - Clinical Feasibility of Brain Radiotherapy Using Synthetic CTs in an MRI-only Workflow N/A
Recruiting NCT05831631 - Characterization of Circulating and Tumor-infiltrating Immune Cells in Malignant Brain Tumors